of CRPC guidelines 2013Castration-resistant prostate cancer (CRPC) includes a wide range of disease types: from patients without metastases or symptoms with rising prostate-specific antigen (PSA) levels despite androgen deprivation therapy (ADT) to patients with metastases and significant debilitation due to cancer symptoms.The panel recommends that ADT be continued in the presence of CRPC (Fig. 1).
No takes yet. Share an insight, caveat, or question.
Saad et al. (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: